Kinshasa, May 28th, 2026 (CPA).– The Industry Promotion Fund (FPI) has reaffirmed its commitment to support the scientific research and the local pharmaceutical production, during a working visit by its Deputy General Director to the Research Centre for Phytotherapy, African Pharmacopoeia and Pharmaceutical Technology (CREPPAT), in Kinshasa, in the Democratic Republic of the Congo. “The FPI intends to support industrial and scientific initiatives capable of transforming Congolese research into concrete solutions for the benefit of the population,” has declared the FPI’s Deputy General Director, Blaise Mastaky, during this visit.
The latter has inspected the research laboratories, quality assurance units and production facilities at CREPPAT, a centre specialising in the transformation of natural products into modern medicines. The centre has presented several products resulting from its research, notably Doubase C, Cancure and Hastro-C M, developed from local natural resources.
According to its managers, these products reflect a commitment to developing therapeutic solutions tailored to African health realities, in a context marked by challenges related to access to medicines and the resurgence of certain diseases on the continent.
Discussions have also focused on the centre’s research into combating Mpox, the Ebola virus, certain cancers, diabetes, high blood pressure, gastric diseases and sickle cell anaemia.
They have reminded that, during the Covid-19 pandemic, the centre had received support from the FPI to conduct randomised controlled clinical trials, carried out in collaboration with researchers from the University of Kinshasa and the University Clinics of Kinshasa. The General Director of CREPPAT has pleaded for the strengthening of the centre’s technical and financial capacities in order to accelerate research and increase the production of ‘Made in Congo’ medicines.
Group photo following the working visit
Kinshasa, May 28th, 2026 (CPA). – The Industry Promotion Fund (FPI) has reaffirmed its commitment to support the scientific research and the local pharmaceutical production, during a working visit by its Deputy General Director to the Research Centre for Phytotherapy, African Pharmacopoeia and Pharmaceutical Technology (CREPPAT), in Kinshasa, in the Democratic Republic of the Congo. “The FPI intends to support industrial and scientific initiatives capable of transforming Congolese research into concrete solutions for the benefit of the population,” has declared the FPI’s Deputy General Director, Blaise Mastaky, during this visit. The latter has inspected the research laboratories, quality assurance units and production facilities at CREPPAT, a centre specialising in the transformation of natural products into modern medicines. The centre has presented several products resulting from its research, notably Doubase C, Cancure and Hastro-C M, developed from local natural resources. According to its managers, these products reflect a commitment to developing therapeutic solutions tailored to African health realities, in a context marked by challenges related to access to medicines and the resurgence of certain diseases on the continent. Discussions have also focused on the centre’s research into combating Mpox, the Ebola virus, certain cancers, diabetes, high blood pressure, gastric diseases and sickle cell anaemia. They have reminded that, during the Covid-19 pandemic, the centre had received support from the FPI to conduct randomised controlled clinical trials, carried out in collaboration with researchers from the University of Kinshasa and the University Clinics of Kinshasa. The General Director of CREPPAT has pleaded for the strengthening of the centre’s technical and financial capacities in order to accelerate research and increase the production of ‘Made in Congo’ medicines.